Differences between bisphosphonates in binding affinities for hydroxyapatite
- 10 November 2009
- journal article
- research article
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 92B (1), 149-155
- https://doi.org/10.1002/jbm.b.31500
Abstract
Bisphosphonates (BPs) inhibit bone resorption and are widely used for the treatment of bone diseases, including osteoporosis. BPs are also being studied for their effects on hydroxyapatite (HAP)-containing biomaterials. There is a growing appreciation that there are hitherto unexpected differences among BPs in their mineral binding affinities that affect their pharmacological and biological properties. To study these differences, we have developed a method based on fast performance liquid chromatography using columns of HAP to which BPs and other phosphate-containing compounds can adsorb and be eluted by using phosphate buffer gradients at pH 6.8. The individual compounds emerge as discrete and reproducible peaks for a range of compounds with different affinities. For example, the peak retention times (min; mean ± SEM) were 22.0 ± 0.3 for zoledronate, 16.16 ± 0.44 for risedronate, and 9.0 ± 0.28 for its phosphonocarboxylate analog, NE10790. These results suggest that there are substantial differences among BPs in their binding to HAP. These differences may be exploited in the development of biomaterials and may also partly explain the extent of their relative skeletal retention and persistence of biological effects observed in both animal and clinical studies. © 2009 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 2010Keywords
This publication has 28 references indexed in Scilit:
- Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitroJournal of Biomedical Materials Research Part A, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- Manipulation of the Anabolic and Catabolic Responses With OP-1 and Zoledronic Acid in a Rat Critical Defect ModelJournal of Bone and Mineral Research, 2005
- Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacyBone, 2005
- Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's DiseaseNew England Journal of Medicine, 2005
- Zoledronic acid causes enhancement of bone growth into porous implantsThe Journal of Bone and Joint Surgery. British volume, 2005
- Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: A randomized trialJournal of Orthopaedic Research, 2005
- Zoledronic Acid Treatment Results in Retention of Femoral Head Structure After Traumatic Osteonecrosis in Young Wistar RatsJournal of Bone and Mineral Research, 2003
- Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2002
- Synthetic and Structural Aspects of Technetium Chemistry as Related to Nuclear MedicinePublished by American Chemical Society (ACS) ,1980